title: Expression of the endocannabinoid system in human first trimester placenta and its role in trophoblast proliferation.
abstract: The endocannabinoid, anandamide, which binds to two major receptor proteins, the cannabinoid receptors (CBs) 1 and 2 (CB1 and CB2), has been shown to play a role in first trimester miscarriage possibly through impairment of the developing trophoblast. Although the precise molecular mechanisms underlying this are unknown, plasma anandamide levels are known to be regulated by the progesterone-induced enzyme, fatty acid amide hydrolase (FAAH). Here, we tested the hypothesis that temporal-spatial expression of FAAH, CB1, and CB2 is regulated during early pregnancy and that anandamide detrimentally alters trophoblast proliferation. Transcripts for CB1, CB2, and FAAH were demonstrated in first trimester trophoblast extracts with only the CB1 transcript being significantly regulated. The significant 4.7-fold increase in expression at wk 10 gestation was reduced to 8.9% of the peak value by wk 12. Transcripts for CB2 showed a similar pattern of expression but were not significantly induced. By contrast, FAAH transcript levels appeared to increase toward the end of the first trimester, but again did not reach significance. These observations were supported by immunohistochemical studies that demonstrated a similar pattern of expression at the protein level, with cellular localization for all three proteins concentrated within the syncytiotrophoblast layer. Anandamide also prevented BeWo trophoblast cell proliferation in a dose-dependent manner, with a 50-60% significant inhibition of cell proliferation with concentrations in excess of 3 mum. This effect was mediated through CB2. Together, these data provide insights into how elevated plasma anandamide levels increase the risk of first trimester miscarriage.
authors.affiliation: Endocannabinoid Research Group, Reproductive Sciences Section, Department of Cancer Studies and Molecular Medicine, University of Leicester, Leicester LE2 7LX, United Kingdom.
authors.forename: Osama M H
authors.initials: OM
authors.lastname: Habayeb
authors.forename: Anthony H
authors.initials: AH
authors.lastname: Taylor
authors.forename: Stephen C
authors.initials: SC
authors.lastname: Bell
authors.forename: David J
authors.initials: DJ
authors.lastname: Taylor
authors.forename: Justin C
authors.initials: JC
authors.lastname: Konje
mesh_terms: D000022:Abortion, Spontaneous / Q000097:blood / Q000453:epidemiology / Q000503:physiopathology; D000581:Amidohydrolases / Q000235:genetics / Q000378:metabolism; D001095:Arachidonic Acids / Q000097:blood / Q000494:pharmacology*; D063385:Cannabinoid Receptor Modulators / Q000097:blood / Q000494:pharmacology*; D002455:Cell Division / Q000502:physiology; D004305:Dose-Response Relationship, Drug; D063388:Endocannabinoids; D005260:Female; D015870:Gene Expression / Q000502:physiology; D006801:Humans; D007150:Immunohistochemistry; D053284:Polyunsaturated Alkamides / Q000097:blood / Q000494:pharmacology*; D011247:Pregnancy; D011261:Pregnancy Trimester, First; D043884:Receptor, Cannabinoid, CB1 / Q000235:genetics* / Q000378:metabolism; D043885:Receptor, Cannabinoid, CB2 / Q000235:genetics* / Q000378:metabolism; D020133:Reverse Transcriptase Polymerase Chain Reaction; D012307:Risk Factors; D014327:Trophoblasts / Q000166:cytology* / Q000378:metabolism / Q000502:physiology*; D000099252:Fatty Acid Amide Hydrolases
chemical_list: D000581:Amidohydrolases; D001095:Arachidonic Acids; D063385:Cannabinoid Receptor Modulators; D063388:Endocannabinoids; D053284:Polyunsaturated Alkamides; D043884:Receptor, Cannabinoid, CB1; D043885:Receptor, Cannabinoid, CB2; D000099252:Fatty Acid Amide Hydrolases; C078814:anandamide